Introduction
The potential harmful and protective effects of sex hormones on cardiovascular disease (CVD) progression have been a matter of controversy over the last decades. The late onset of CVD in women, when compared with men, has been attributed to the protective effects of oestrogen during reproductive years and is lost after menopause. 1 In males, low levels of circulating testosterone have been associated with an increased risk of atherosclerotic manifestations, but results have been inconsistent and contradictory. 2, 3 Normalization of testosterone levels in a large cohort of elderly male veterans has shown convincing results with a significant reduction in all-cause mortality, myocardial infarction (MI), and stroke. 4 That said, the underlying pathophysiological phenomenon leading up to these health benefits remains poorly understood. A possible shortcoming of previous studies reporting on the effects of sex hormones on CVD is that these studies often focused on the individual effects of either testosterone or oestradiol. Synergistic effects or codependency of oestradiol on testosterone are thereby missed. In male patients, for instance, most oestradiol production occurs via conversion of testosterone to oestradiol through aromatase in white adipose tissue, making oestradiol dependent of both circulating free testosterone and aromatase. 5 The interplay between these two key players on vascular function can be assessed by calculating the ratio of testosterone to oestradiol (T/E2) in males or the oestradiol to testosterone ratio (E2/T) in females.
The first results of focusing on T/E2 ratio in males and E2/T ratio in females on CVD have been promising and show that a disturbance of the normal physiological balance could contribute to CVD progression. [6] [7] [8] A T/E2 imbalance rather than the absolute levels of androgens associated with the development of coronary artery disease (CAD) in a cohort of 115 male patients. 7 Furthermore, androgen replacement therapy with the aim to restore an adequate E2/T ratio suppressed the development of atherosclerosis by reducing lipid lesions, decreasing endothelial cell injury, modulating the coagulation system, and reduction of inflammatory processes. 6 Another recent study focusing on soluble glycoprotein130 (SGP130), a natural antagonist of interleukin-6 (IL6) trans-signalling, showed a strong positive correlation with T/E2 ratio in 254 male CAD patients. 8 Although these results seem compelling they have been obtained in small studies or in experimental animal models only.
In order to investigate the interplay of sex hormones and CVD, we investigated the underlying culprit of CVD, namely the atherosclerotic plaque, and sex hormones in a cohort of 611 men undergoing carotid endarterectomy (CEA). We studied histological plaque characteristics, inflammatory plaque proteins, and blood biomarkers together with 3 year follow-up and their association with T/E2 ratio in these men.
Methods

Study population
The Athero-Express Biobank Study (AE) is a prospective ongoing biobank, which includes blood and atherosclerotic plaque specimens as well as extensive baseline characteristics and 3 year follow-up data from patients undergoing CEA. The study design is described previously in more detail. 9, 10 In brief, since 2002 all patients scheduled for CEA in the St Antonius Hospital Nieuwegein or the University Medical Centre Utrecht (UMC Utrecht) were asked to participate in the AE. Indications for CEA were reviewed by a multidisciplinary vascular team and experienced surgeons performed the endarterectomy in accordance with local and international guidelines. [11] [12] [13] [14] Patient characteristics are obtained through standardized preoperative questionnaires and from hospital medical records. Medical ethics committees of both participating centres approved the study protocol, and all of the included patients provided written informed consent. The study is conducted in accordance with the declaration of Helsinki. All males with sex-hormone level measurements above the detection limit and complete 3 year follow-up were included in the present study. Atherosclerotic plaques specimens, blood, and patient characteristics were collected between 2002 and 2016.
Tissue collection and plaque processing
Atherosclerotic plaque specimens collected during CEA were immediately processed after surgery according to a standardized protocol. Briefly, after removal, the carotid plaques were divided into crosssectional segments of 5 mm thick. The segment with the greatest plaque burden was classified as a culprit lesion and subjected to histological examinations. The culprit lesion was routinely stained for assessment of calcification (haematoxylin-eosin), collagen (picrosirius red), lipid core (haematoxylin-eosin, picrosirius red), macrophages (CD68), smooth muscle cells (a-actin), intraplaque haemorrhage (haematoxylin-eosin, Elastin von Gieson), vessel density (CD34), and neutrophils (CD66b). 10 The amount of collagen and calcification were scored semi-quantitatively at a 40Â microscopic magnification and grouped in no/minor and moderate/heavy staining. Computerized analyses were used to quantify macrophages and smooth muscle cells infiltration. The size of lipid core was assessed using polarized light and plaques with lipid content >40% were classified as atheromatous. CD34-positive microvessels were scored in the three areas of the plaque with the highest microvessel density and expressed as an average number of vessels per hot spot. 15 The number of neutrophils was determined by counting the CD66b-positive cells per plaque, as described before. 10 Figure 1 shows one example of a single atherosclerotic plaque stained for histological assessment. All histologic slides were assessed and showed good inter-and intra-observer variability (j 0.6-0.9). 16 Additional cytokine and chemokine protein levels were measured in a selection of atherosclerotic plaque specimens (n = 333). Measurements were performed in isolates after Tripure (Roche) protein isolation. IL-6, interleukin-6 receptor (IL-6R), interleukin-8 (IL-8), adiponectin, macrophage colony stimulating factor 1, and monocyte chemotactic protein 1 (MCP1) levels were measured at the in-house Luminex core facility (Whilhemina Children's Hospital, UMC Utrecht, the Netherlands).
Blood collection and sex-hormone measurements
All blood samples were collected prior to surgical incision. In 611 male patients sufficient blood was available for measurements of both sex hormones. Preoperative lithium-heparin EDTA plasma, stored at -80 C, was used for the sex-hormone measurements. Plasma testosterone and oestradiol were measured by immunoassay on an ARCHITECT ci8200 system (Abbott Diagnostics, Abbott Laboratories, USA) at the Laboratory of Clinical Chemistry and Hematology of the University Medical Centre Utrecht. The T/E2 ratio was calculated using the following formula: Testosterone/(10*Oestradiol). 
Haematological measurements
For this study, data from the Utrecht Patient-Oriented Database (UPOD) was used. UPOD is an infrastructure of relational databases comprising data on patient characteristics, hospital discharge diagnoses, medical procedures, medication orders, and laboratory tests for all patients treated at the University Medical Center Utrecht, since 2004. All haematological parameters were measured using the Abbott CELL-DYN Sapphire. The CELL-DYN is an automated haematology analyser using laser light scattering, electrical impedance, and spectrophotometry to characterize morphological traits of white blood cells, red blood cells, and platelets. Irrespectively of the clinician's request, the CELL-DYN will perform a complete blood count, only the requested results are reported to the physician, however, all results are stored in UPOD for research purposes. UPOD data acquisition and management is in accordance with current regulations concerning privacy and ethics. The structure and content of UPOD have been described in more detail previously. 17 For the current study, haematological measurements were selected within a 1 month preoperative range. Measurement closest to the moment of surgery was used for analyses. In 351 males a preoperative blood draw was available for analysis.
Follow-up
After the initial procedure, patients included in the AE undergo 3 year follow-up. Three year follow-up data were obtained through annual questionnaires addressing the occurrence of cardiovascular events and/ or hospitalizations. If a questionnaire is answered positively, cardiovascular events were validated using hospital data systems or health records kept by the general practitioner. Furthermore, all events were assessed by two members of an outcome assessment committee. If patients did not respond, their general practitioner was contacted. A major adverse cardiovascular event (MACE) was defined as MI, stroke, or cardiovascular death. Cardiovascular death was defined as one of the following: fatal MI, fatal stroke (either bleeding or ischaemic), fatal ruptured abdominal aneurysm, fatal heart failure, or sudden death. In patients who reached multiple endpoints during follow-up, only the first manifestation of a cardiovascular event was used for analysis.
Statistical analyses
Both sex-hormone levels and clinical follow-up were available for 611 patients. Patients were stratified into quartiles based on their calculated T/E2 ratio; Q1: <0.9878 (n = 152), Q2: 0.9878-1.4191 (n = 153), Q3: 1.4192-1.8916 (n = 153), and Q4: >1.8916 (n = 153). A flowchart of patient stratification and studies performed was provided in Supplementary material online, Figure S1 . Plaque characteristics were available for 500 patients included in this study. The v 2 tests were used to compare categorical baseline characteristics of patients across the different T/E2 ratio groups, one-way ANOVA for continuous, normally distributed variables and the Kruskall-Wallis tests for continuous, nonnormally distributed variables. To test the association between the calculated T/E2 ratio and plaque characteristics, multivariate logistic regression analyses with correction for possible confounders were performed. Baseline characteristics that differed in univariate analyses over the T/E2 ratio groups (P < 0.2) and associated with the plaque characteristic of interest (P < 0.2) were considered possible confounders. Furthermore, to examine the risk of future cardiovascular events in relation to the T/ E2 ratio, a multivariable cox proportional hazard model was used. Due to relative small power in the survival analyses, Q1 þ Q2 were grouped together to serve as the low T/E2 ratio group and Q3 þ Q4 were grouped together to serve as the high T/E2 ratio group. Possible confounders were selected based on both a univariable analysis and empirical evidence. Variables that were added to the final model were: age, BMI, diabetes mellitus, kidney function, contralateral stenosis, high-density lipoprotein (HDL)-cholesterol, and history of CAD. Measured levels of plaque cytokines and chemokines required logarithmic transformation in order to enter them into linear regression models. The effect of T/E2 ratio on the different outcomes is expected to be affected by aromatase in white adipose tissue. Favourably this aromatase activity would be quantified and added to the multivariate models. Unfortunately this metabolic activity is hard to measure, and therefore, interpretation of these analyses should be done with acknowledgement of this serious limitation. The BMI, however, is a good measure for body composition and is likely to be related with adipose tissue. In order to appreciate this interplay between T/E2 ratio, body composition and cardiovascular events, BMI stratification analyses were performed after BMI interaction was proven to be highly significant. Missing data were handled by multiple imputation in order to prevent incomplete case analyses in multivariate models. 18 All statistical tests were performed in SPSS version 21 . A twosided P-value <0.05 was considered significant.
Results
Baseline characteristics
Baseline characteristics of the 611 male patients stratified by T/E2 quartiles are presented in Table 1 . Moreover in Supplementary material online, Figure S2 a scatterplot was added demonstrating the testosterone and oestradiol concentrations across the different T/E2 quartiles. Mean testosterone and oestradiol concentrations were 12.3 nmol/L (SD ± 5.56) and 92.8 pmol/L (SD ± 38.44), respectively. Testosterone concentrations in the study population were low but normally distributed. The low concentrations of testosterone in the study population are in line with testosterone concentrations of men the same age in the general population. 19 Age and most other cardiovascular risk factors, such as smoking and hypertension, did not differ across the different T/E2 ratio groups. Patients with low T/E2 ratios had a high body mass index (BMI) (P < 0.001) and more often had comorbidities associated with overweight such as diabetes mellitus. Conversely, patients with high T/E2 ratio had higher low-density lipoprotein, HDL, and total cholesterol levels while triglyceride levels were comparable in all groups. Indication for surgery (i.e. asymptomatic, transient ischaemic attacks, amaurosis fugax, or stroke) did not differ across the different T/E2 ratio groups.
Plasma biomarkers
Plasma inflammatory biomarkers stratified by T/E2 ratio groups are presented in Table 2 . Patients within the lowest T/E2 ratio group had higher levels of C-reactive protein (CRP) in comparison to the other T/E2 ratio groups (P < 0.001). Moreover, the measurements showed a consistent direction of effect over all ratio groups. Patients with low T/E2 ratio had higher number of blood leucocytes when compared with patients with high T/E2 ratio (P = 0.001). The higher leucocyte counts in the blood of patients in the lowest T/E2 ratio group can be attributed to the higher number of neutrophils (P = 0.005) and monocytes (P = 0.038).
The neutrophil-to-lymphocyte ratio which is a strong predictor for future adverse events and reflects inflammatory status in CVD patients, was lowest in patients with high T/E2 ratio and showed an direction of effect over the four groups, however, not reaching statistical significance (P = 0.385). 20 
Plaque histology
Results from univariate and multivariate plaque analyses are presented in Table 3 . In univariate analyses, T/E2 ratio was negatively associated with plaque calcifications, the percentage of macrophage staining, and the total number of plaque neutrophils. After multivariate correction T/E2 ratio was independently associated with moderate/heavy plaque calcifications and the total number of neutrophils per plaque. In addition, even though not reaching statistical significance, six out of eight plaque characteristics showed negative trends of effect with T/E2 ratio. Moreover, one important plaque characteristic showing a positive trend with T/E2 ratio was collagen staining, this is the plaque feature best characterizing stable atherosclerotic lesions. To test the overall direction of effect of T/E2 ratio and features associated with the vulnerability of the atherosclerotic plaque we performed binomial testing. This correlation showed a negative association of T/E2 with vulnerable plaque features (P = 0.031).
Plaque proteins
Proteins were isolated from 333 atherosclerotic plaque specimens. Plaque protein content stratified by the four T/E2 groups is presented in Table 4 . Correlation plots of the different cytokine and chemokine levels with T/E2 ratio are presented in 
Clinical outcomes
For the outcome analyses Q1 and Q2 were binned together into the low T/E2 ratio group and Q3 and Q4 in the high T/E2 ratio group. Clinical follow-up data was available for 611 male patients included in the Athero-Express. During a mean follow-up of 2.7 years, 72 patients (11.8%) reached a major cardiovascular endpoint. Forty patients (6.5%) suffered from stroke, 18 patients endured an MI (2.9%), and in total 24 patients (3.9%) died due to cardiovascular causes. All adverse outcomes and results of the multivariate analyses are presented in Table 5 . After correction for possible confounders (age, BMI, diabetes mellitus, estimated glomerular filtration rate, HDL-cholesterol, contralateral stenosis, and history of CAD) with the use of a multivariable Cox regression model, T/E2 ratio was an independent predictor for the occurrence of MACE {hazard ratio low T/E2 ratio; 1.67 [95% confidence interval (CI) 1.02-2.76] P = 0.043} (Figure 3) . Moreover low T/E2 was associated with an increased incidence of stroke during 3 year follow-up [hazard ratio (HR) 2.09 (95% CI 1.06-4.14) P = 0.034] (Figure 4) . All-cause mortality showed a trend towards poor survival in patients with low T/E2 ratio, which is in line with the increased incidence of major events however not reaching statistical significance (P = 0.150) (Figure 5 
BMI interaction and stratified results
In Supplementary material online, Table S1 data of the multivariate model with and without BMI is displayed. The hazard ratio of T/E2 ratio on major events changed from 1.67 to 1.58 with the addition of BMI. This suggests that BMI is not explaining the relation between T/E2 and outcome and is not a confounder. To identify whether the relation of T/E2 on outcome was dependent on high or low BMI, interaction was tested. After a significant interaction was found, the data was stratified for low and high BMI groups (BMI <25 and BMI > _25 
Figure 2
The correlation between T/E2 ratio and plaque proteins. Scatter diagrams illustrate the correlation between circulating T/E2 ratio and cytokine and chemokines in plaques obtained from male patients after carotid endarterectomy (based on log transformed data). IL-6, interleukin 6; IL-6R, interleukin-6 receptor; IL-8, interleukin 8; MCSF, macrophage colony stimulating factor 1; MCP1, monocyte chemotactic protein 1. anti-inflammatory marker adiponectin is strongest in the normal BMI group. These interaction analyses show that the effects we found on secondary outcome and plaque proteins are strongest in men with elevated BMI.
Individual sex-hormone analyses
To exhibit the clear added value in using T/E2 ratio over individual hormone measurements additional analyses have been performed for the individual testosterone and oestradiol levels and these results are provided in Supplementary material online. As illustrated by Supplementary material online, Tables S3-S5 , testosterone levels alone were not associated with plaque features and a modest negative correlation with inflammatory markers in the blood was seen. For the individual oestradiol measurements as illustrated in Supplementary material online, Tables   S6-S8 , no correlation with inflammatory blood biomarkers was seen but a positive correlation with percentage of smooth muscle cells [B = 0.068 (P = 0.008)]. In univariate survival analyses, low levels of testosterone were associated with secondary stroke, however, this association lost statistical significance after correction for possible confounders (Supplementary material online, Table S9 ).
Discussion
To our best knowledge, this is the first study reporting on the T/E2 ratio in a large cardiovascular cohort in which atherosclerotic plaques, patient characteristics, and 3 year follow-up were available. The current study shows that men with low T/E2 ratio have an increased risk for development of MACE during 3 year follow-up independent of known cardiovascular risk factors. Low T/E2 ratio showed an overall trend towards T/E2 ratio is associated with future MACE histological features, which represent the vulnerability of atherosclerotic plaques. Moreover, we show that the T/E2 ratio reflects both systemic and plaque inflammation, as assessed by levels of CRP and leucocyte counts in blood and IL-6 in the plaque, possibly explaining the poor outcome after carotid revascularization. Considering that interaction analyses showed that these effects were predominantly found in men with elevated BMI, our results are expected to be affected by aromatase activity in white fat tissue. In the last decades, cardiovascular research focusing on the individual effects of testosterone and oestradiol has provided inconsistent and contradictory evidence. Both positive and negative associations between the two sex hormones and mortality have been found in men. 21, 22 Nevertheless, more recent findings suggest that testosterone and oestradiol may have opposing effects on cardiovascular risk factors and the progression of CVD. 23 For instance, low levels of testosterone but high levels of oestradiol have been associated with increased intima-media thickness, a widely recognized marker for atherosclerosis. 23 In addition, several studies have demonstrated that testosterone has antiinflammatory effects, 24, 25 whereas oestradiol has pro-inflammatory effects. 26, 27 These findings all show that a disrupted hormonal balance is associated with poor vascular function and increased systemic inflammation. It can of course be postulated that these associations are indirect in nature and the T/E2 ratio is merely reflective of het inflammatory processes and aromatase activity in white adipose tissue.
To further expand on our understanding of the interaction between BMI, T/E2 ratio, and future MACE, we have performed interaction and stratified analyses. We show that BMI is an important effect modifier of T/E2 ratio on future events. Men with elevated BMI and decreased T/E2 ratio had the highest risk of developing future MACE, whereas in men without elevated BMI this risk was no longer statistically significant. These different effects in patients with different body composition might explain different traits of adipose tissue apart from total volume. Adipose tissue is distributed throughout the human body in two main compartments namely the subcutaneous compartment and the visceral compartment. 28 In males this distribution is typically apple-shaped and represents visceral/abdominal adipose tissue (VAT), whereas in females fat distribution is more pear shaped and represents subcutaneous adipose tissue (SAT). 29 The mechanisms by which sex-hormones regulate energy balance and adiposity is not fully understood but it has been shown that VAT express higher concentrations of androgen receptors while SAT expresses higher concentrations of oestrogen receptors. 30 More importantly, SAT exerts protective effects, whereas VAT induces harmful metabolic alterations and increases the risk of CVD. 31, 32 The effects on the cardiovascular system are partially exerted by the endocrine effects of VAT since it expresses key inflammatory players such as TNFa, IL-6, and PAI-1 which strongly affects inflammatory processes throughout the body. SAT, however, is less metabolically active and produces protective effects such as adiponectin and leptin. 33 As presented by the BMI-stratified results it appears that the effects we find are largely driven by T/E2 abnormalities in patients with BMI > _25. Since all patients are males it is likely that a contributing factor to poor prognosis and increased inflammation is indeed induced by the endocrine effects of VAT.
And it is possible that T/E2 ratio reflects the aromatase activity, and might therefore, be a marker of total VAT volume and increased cardiovascular risk. In overweight men, T/E2 ratio may thus serve as risk marker of VAT and identify high-risk patients that may require more intensive monitoring after cardiovascular interventions. Recent findings state that T/E2 ratio is associated with the antiinflammatory protein SGP130, 8 moreover, this the same study showed the synergistic effect of testosterone and oestradiol on SGP130 levels in culture supernatant of human umbilical vein endothelial cells (HUVECs).
The anti-inflammatory properties of SGP130 have mainly been attributed to endogenous inhibition of IL-6 trans-signalling; a decrease in SGP130 would result in a decrease of these anti-inflammatory capacities. To further expand on these mechanisms leading up to diminished vascular function, we measured a range of inflammatory cytokines and chemokines in the atherosclerotic plaque. Within the present study, we show that T/E2 ratio was inversely associated with IL-6 and IL-6R concentrations in the plaque. The increased Il-6 and IL-6R concentrations in the atherosclerotic plaque of patients with decreased T/E2 ratio suggests an inflammatory pathway affected by hormonal misbalance. Our results are in line with these studies showing lowered T/E2 ratio associated with decreased vascular function and increased incidence of future CVD onset, however, if these effects are direct through the actions of T/E2 ratio or an indirect effect through the added risk of VAT remains uncertain. [6] [7] [8] 34, 35 An important consideration when studying T/E2 ratio is the enzyme aromatase, which is responsible for the transformation of androgens into oestrogens. This aromatization step is responsible for most production of oestradiol in men and occurs predominantly in white adipose tissue. 5 Male patients with a mutation in the gene coding for aromatase and the corresponding knockout mouse model showed similar features of a disturbed T/E2 balance as the current CEA-population. 36 These patients suffered from early onset of atherosclerosis, increased VAT (present in the current cohort as a higher BMI in patients with a lower T/E2 ratio) and a disturbed glucose homeostasis (present in the current cohort as an increased incidence of diabetes mellitus in patients with a lower T/E2 ratio). Patients with a mutation in the gene coding for aromatase logically have a high T/E2 ratio, which is in contrast to the patients with poor outcome after CEA in the present analysis that have a lowered T/E2 ratio. Not to mention, Zheng et al. 7 showed a higher T/E2 ratio in CAD Figure 5 Adjusted event curves for T/E2 ratio and death after carotid endarterectomy using Cox proportional-hazards model. patients in comparison to age-matched healthy controls. Nevertheless, the mean T/E2 ratio in the above-mentioned control groups was similar to the mean T/E2 ratio of patients in the higher quartiles for the T/E2 ratio in the current cohort. These studies suggest that in CVD the optimal concentrations curves of testosterone and oestradiol could be U-shaped. Either concentrations that are on the high or low range of normal could impair vascular function and promote clot formation. Hence, disequilibrium between testosterone and oestradiol, resulting in either too high or too low T/E2 ratio, might contribute to CVD progression. This said, when assessing sex hormones in CVD-patients the T/E2 ratio should always be combined with the individual levels of testosterone and oestradiol for appropriate understanding of hormonal status. The T/E2 ratio can then serve as a practical tool to determine CVD-risk, especially in overweight men.
Future implications
Future efforts in restoring hormonal balance in order to further reduce cardiovascular risk and preserve vascular function should not merely try to improve just one of both sex hormones. The present study provides important insights in how hormonal dysregulation is associated with increased systemic inflammation, inflammation within the atherosclerotic plaque, and poor outcome. Moreover, we provide essential insights through which pathophysiological mechanisms obesity influences cardiovascular function and outcomes. Considering the unknown role of aromatase activity in this interaction which is suggested by the different outcomes in the BMI strata we can only speculate on the effects of clinical aromatase inhibition (AI). In a recent small (n = 29) proof-of-concept trial no clear cardio metabolic benefits were seen in men receiving AI. 37 A small reduction in levels of CRP was visible; however, possibly due to small sample size these differences were not statistically significant. In females there is more evidence on the cardiovascular effects of AI, since these agents are used in the treatment of oestrogen receptor positive breast cancer. A large observational study (n = 9350) showed an increases risk for MI [HR 2.02 (95% CI 1.16-3.53 )] in women receiving AI compared with women receiving Tamoxifen. 38 Considering these results, we expect AI to have no beneficial cardiovascular effects in women and in men these effects remain largely unknown.
Strengths and limitations
The current study suffers from some limitations, first, the production of oestradiol via aromatase occurs predominantly in white adipose tissue. As a consequence, males with higher BMI will show decreased T/E2 ratios. This effect was also present in our cohort (P < 0.001) and it could be suggested that the poor outcome after CEA is caused by obesity and not T/E2 ratio. In multivariate analyses, however, we corrected for this possible confounder and show that decreased T/E2 ratio was a risk factor for major events during follow-up, independent of BMI or obesity. Moreover, in univariate logistic regression analysis BMI was not associated with the occurrence of future MACE [HR 0.96 (95% CI 0.89-1.04 P = 0.321)] while T/E2 strongly predicts future events. Implicating that T/ E2 ratio had prognostic value for MACE independent of BMI. One could argue that BMI does not accurately represent the degree of abdominal adipose tissue and could advocate the use of waist circumference. Nonetheless, it has been shown that BMI and waist circumference similarly estimate the degree of abdominal adipose tissue in males. 39 Lastly the activity of aromatase activity in human subjects is difficult to quantify. However, T/E2 proved to be predictive for MACE, independent of BMI. BMI alone had no predictive value in our cohort. Concluding, in male patients with manifest atherosclerotic disease, low T/E2 ratio was associated with increased systemic inflammation, increased inflammatory plaque proteins and an increased risk of future MACE as compared with men with normal T/E2 ratio. These effects are strongest in men with elevated BMI and are expected to be affected by aromatase activity in white fat tissues. Normalization of T/E2 ratio may be a useful tool for the secondary prevention of CVD in men. T/E2 ratio is associated with future MACE
